MediWound

MDWD

Market cap $222M

MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5 th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- MediWound Ltd.

MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17 , 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that its management team will present at the following upcoming investor conferences : Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Time: 10:40 a.

MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference

MediWound Reports New Clinical Data Demonstrating NexoBrid ® 's Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries

MediWound Ltd. ( MDWD ) Q3 2025 Earnings Call November 20, 2025 8:30 AM EST Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President of Strategy & Corporate Development Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Joshua Jennings - TD Cowen, Research Division Swayampakula Ramakanth - H.C.

MediWound (MDWD) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.98 per share a year ago.

Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid ® Facility; Full Operational Capacity Expected by Year-End 2025 Balance Sheet Strengthened with $30 Million Equity Financing Third Quarter 2025 Revenue of $5.4 Million, Up 23% Year-over-Year Conference Call Today, November 20, 2025, at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd.

MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd.

MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid ®

MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares